Literature DB >> 25608696

Pathophysiology of infantile pulmonary arterial hypertension induced by monocrotaline.

Marina Dias-Neto1, Ana Luísa-Neves, Sónia Pinho, Nádia Gonçalves, Maria Mendes, Catarina Eloy, José M Lopes, Daniel Gonçalves, Manuel Ferreira-Pinto, Adelino F Leite-Moreira, Tiago Henriques-Coelho.   

Abstract

Pediatric pulmonary arterial hypertension (PAH) presents certain specific features. In this specific age group, experimental models to study the pathophysiology of PAH are lacking. To characterize hemodynamic, morphometric, and histological progression as well as the expression of neurohumoral factors and regulators of cardiac transcription in an infantile model of PAH induced by monocrotaline (MCT), eight-day-old Wistar rats were randomly injected with MCT (30 mg/kg, sc, n = 95) or equal volume of saline solution (n = 92). Animals were instrumented for biventricular hemodynamic recording 7, 14, and 21 days after MCT, whereas samples were collected at 1, 3, 7, 14, and 21 days after MCT. Different time point postinjections were defined for further analysis. Hearts and lungs were collected for morphometric characterization, assessment of right- and left-ventricle (RV and LV) cardiomyocyte diameter and collagen type-I and type-III ratio, RV collagen volume fraction, and pulmonary vessels wall thickness. mRNA quantification was undertaken for brain natriuretic peptide (BNP), endothelin-1 (ET-1), and for cardiac transcription regulators (HOP and Islet1). Animals treated with MCT at the 8th day of life presented RV hypertrophy since day 14 after MCT injection. There were no differences on the RV collagen volume fraction or collagen type-I and type-III ratio. Pulmonary vascular remodelling and PAH were present on day 21, which were accompanied by an increased expression of BNP, ET-1, HOP, and Islet1. The infantile model of MCT-induced PAH can be useful for the study of its pathophysiology and to test new therapeutic targets in pediatric age group.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25608696     DOI: 10.1007/s00246-015-1111-y

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  34 in total

1.  Pulmonary arteritis produced in rat by feeding Crotalaria spectabilis.

Authors:  J J LALICH; L MERKOW
Journal:  Lab Invest       Date:  1961 Jul-Aug       Impact factor: 5.662

2.  Endothelial dysfunction in pulmonary hypertension.

Authors:  J Loscalzo
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

Review 3.  Recent advances in cardiac development with therapeutic implications for adult cardiovascular disease.

Authors:  Jonathan A Epstein; Michael S Parmacek
Journal:  Circulation       Date:  2005-07-26       Impact factor: 29.690

Review 4.  A heart full of stem cells: the spectrum of myocardial progenitor cells in the postnatal heart.

Authors:  Christof Stamm; Yeong-Hoon Choi; Boris Nasseri; Roland Hetzer
Journal:  Ther Adv Cardiovasc Dis       Date:  2009-05-14

5.  Toxicity of pyrrolizidine alkaloids.

Authors:  A R Mattocks
Journal:  Nature       Date:  1968-02-24       Impact factor: 49.962

6.  Homeobox protein Hop functions in the adult cardiac conduction system.

Authors:  Fraz A Ismat; Maozhen Zhang; Hyun Kook; Bin Huang; Rong Zhou; Victor A Ferrari; Jonathan A Epstein; Vickas V Patel
Journal:  Circ Res       Date:  2005-03-24       Impact factor: 17.367

7.  A case of spontaneous resolution of idiopathic pulmonary hypertension.

Authors:  A Fujii; M Rabinovitch; E C Matthews
Journal:  Br Heart J       Date:  1981-11

8.  Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop.

Authors:  Hyun Kook; John J Lepore; Aaron D Gitler; Min Min Lu; Wendy Wing-Man Yung; Joel Mackay; Rong Zhou; Victor Ferrari; Peter Gruber; Jonathan A Epstein
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

9.  Endogenous production of ghrelin and beneficial effects of its exogenous administration in monocrotaline-induced pulmonary hypertension.

Authors:  Tiago Henriques-Coelho; Jorge Correia-Pinto; Roberto Roncon-Albuquerque; Maria J Baptista; André P Lourenço; Sílvia Marta Oliveira; Ana Brandão-Nogueira; Antónia Teles; José M Fortunato; Adelino F Leite-Moreira
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-08-26       Impact factor: 4.733

10.  Regression of primary pulmonary hypertension.

Authors:  P D Bourdillon; C M Oakley
Journal:  Br Heart J       Date:  1976-03
View more
  4 in total

1.  Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.

Authors:  Wei Zhuang; Guili Lian; Bangbang Huang; Apang Du; Genfa Xiao; Jin Gong; Changsheng Xu; Huajun Wang; Liangdi Xie
Journal:  Exp Biol Med (Maywood)       Date:  2018-08-12

2.  Distinct time courses and mechanics of right ventricular hypertrophy and diastolic stiffening in a male rat model of pulmonary arterial hypertension.

Authors:  Ethan D Kwan; Daniela Vélez-Rendón; Xiaoyan Zhang; Hao Mu; Megh Patel; Erica Pursell; Jennifer Stowe; Daniela Valdez-Jasso
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-08-27       Impact factor: 5.125

3.  Modafinil improves monocrotaline-induced pulmonary hypertension rat model.

Authors:  Hyeryon Lee; Kwan Chang Kim; Min-Sun Cho; Suk-Hyo Suh; Young Mi Hong
Journal:  Pediatr Res       Date:  2016-03-09       Impact factor: 3.756

4.  Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.

Authors:  Arnica Behringer; Manuela Trappiel; Eva Maria Berghausen; Henrik Ten Freyhaus; Ernst Wellnhofer; Margarete Odenthal; Florian Blaschke; Fikret Er; Natig Gassanov; Stephan Rosenkranz; Stephan Baldus; Kai Kappert; Evren Caglayan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-01-07       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.